A number of other research analysts also recently weighed in on the company. Cleveland Research began coverage on Covetrus in a report on Friday, May 10th. They set a hold rating on the stock. Stifel Nicolaus began coverage on Covetrus in a report on Wednesday, May 22nd. They set a hold rating and a $30.00 price target on the stock. Zacks Investment Research downgraded Covetrus from a buy rating to a hold rating in a report on Wednesday, July 17th. Finally, Guggenheim began coverage on Covetrus in a report on Thursday, May 23rd. They set a neutral rating on the stock. Six investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Covetrus presently has an average rating of Hold and a consensus target price of $25.75.
Shares of CVET stock opened at $14.85 on Tuesday. Covetrus has a 1-year low of $12.22 and a 1-year high of $43.83. The company has a current ratio of 1.74, a quick ratio of 0.93 and a debt-to-equity ratio of 0.51. The company’s fifty day simple moving average is $23.40.
Covetrus, Inc engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships, and successful financial outcomes for veterinary professionals. The company was founded on April 13, 2018 and is headquartered in Melville, NY.
Featured Story: Why do analysts give a neutral rating?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Covetrus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covetrus and related companies with MarketBeat.com's FREE daily email newsletter.